Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: 

• Rationale for targeting PARP in prostate cancer with ARI combinations
• Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
• FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations 
• Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
• Tips for optimal coordination between pathology and medical oncology

Presenters: 

Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington

Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.

Link to full program: 
https://bit.ly/3PFagxb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.